A cluster of suspected Pneumocystis carinii Pneumonia following intensive chemotherapy in a Belfast haematology unit. by Ong, Y. L. & Jones, F. G.
The Ulster Medical Journal, Volume 67, No. 2, pp. 104-109, November 1998.
A cluster of suspected pneumocystis carinii pneumonia
following intensive chemotherapy in a Belfast
haematology unit
YLOng, FGC Jones
Accepted 25 June 1998
SUMMARY
Five cases of pneumocystis carinii pneumonia were diagnosed in adult patients following
intensivechemotherapyintheRoyalGroupofHospitalshaematologyunit,Belfast,withinaspace
ofsixmonths.Thecommonfeaturesandtheriskfactorscontributingtotheincreasedsusceptibility
of these patients are discussed, as are the likely mechanisms oftransmission ofinfection.
INTRODUCTION
Pneumocystis carinii pneumonia (PCP) is a
potentially life-threatening opportunistic
infection. It was first recognised in Europe as a
distinct clinical entity in children immune-
suppressedbymalnourishmentduringtheSecond
World War. There was renewed interest in
pneumocystis in the early 1980s when it became
recognised as the AIDS defining pulmonary
infection. Pneumocystisisaunicellularorganism
discoveredbyChagasin 1909.Itwassubsequently
shown to be a fungus as a result of RNA
sequencing.1 Therearerecentreportsofincreasing
incidence of this infection following organ
transplantation due to high-dose immuno-
suppressive agents.
We report a cluster of five suspected cases of
pneumocystis carinii pneumonia in the regional
haematology unit, Royal Group of Hospitals,
Belfast,betweenAugust 1995 andFebruary 1996.
Case records for these patients were retrieved
and studied in detail. Clinical course, treatment
and survival outcome were followed up. We also
review the literature on this subject and compare
it with our own experience.
Patient 1 (index case)
A 28-year-old male with acute monocytic
leukaemiapresentedwithlethargyandbonepain.
He achieved complete remission following the
first course of chemotherapy MAE 3+10+5
(Mitozantrone 12 mg/M2 daily i.v. on days 1, 3
and 5; cytarabine 100 mg/m2 12 hourly i.v. on
days 1-10 inclusive, and etoposide 100 mg/M2
daily i.v. on days 1-5 inclusive). He experienced
severe nausea during chemotherapy unrelieved
by ondansetron, domperidone, cyclizine or
metoclopramide. Dexamethasone 4 mg 8-hourly
was subsequently used with good effect.
Dexamethasone was also used prophylactically
with his second course MAE 3+8+5. He
subsequently developed febrile neutropenia.
Central andperipheral blood cultures were taken
prior to commencing teicoplanin, ciprofloxacin
and netilmicin. He was allergic to penicillin.
Fluconazole 200 mg i.v. daily was added two
days later when his pyrexia failed to settle.
Coliformbacilliwereisolatedfrombloodculture.
Sensitivitytestingconfirmedthathewasreceiving
the right antibacterial therapy.
However, two weeks later, he remained pyrexic
despitebone marrowrecovery as indicatedbythe
rise in his leukocyte count. This was followed by
arapidclinical deterioration. Hedevelopedanon
productivecough,experiencedshortnessofbreath
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at rest and had difficulty in drawing a deep
breath. He was cyanosed, tachypnoeic with sinus
tachycardia 120 bpm. Chest expansion and air
entry were restricted bilaterally. There were fine
crepitations in the midzones and bases. Chest
radiograph revealed bilateral interstitial hazy
shadowing consistent with PCP, compared to a
normalchestradiographfourdaysearlier. Arterial
blood gas analysis was contraindicated by the
thrombocytopenia. Broncho-alveolarlavagewas
discussed but deemed inexpedient as the
bronchoscopyunitwaslocatedintheBelfastCity
Hospital and a transferjourney by an ambulance
wouldberequired. Hewashypoxicanddependent
onhigh-flow oxygen. Decision was madeto start
empirical treatment without delay. Intravenous
co-trimoxazole(trimethoprim-sulfamethoxazole)
at 1.92 gram q.d.s. and dexamethasone 10 mg
daily was started immediately. The use of high-
flow oxygen, saline nebuliser and chest
physiotherapy failed to induce any sputum for
examination. Within 48 hours, there was
significant clinical improvement, accompanied
by resolution on the chest radiograph. Two days
laterhewas wellenoughtobedischargedonhigh
dose oral co- trimoxazole.
He continued on co-trimoxazole at the
prophylactic dose of 480 mg b.d. thrice weekly
with no recurrence of PCP at 14 months.
Unfortunately, he succumbed to the acute
leukaemia 15 months following diagnosis.
Patient 2
A 26-year-old male with acute lymphoblastic
leukaemia developed an acuterespiratory illness
aftertwomonthsofintensivemultidrugcytotoxic
regime containing high dose prednisolone
(UKALL 12 MRC protocol). Initially, he was
pyrexic without respiratory symptoms.
Intravenous antibacterial treatment with benzyl
penicillin, netilmicin and ciprofloxacin was
commenced following blood cultures. When
pyrexia failed to settle after 48 hours, he was
switchedtosecondlineceftazidimeandamikacin.
Intravenousfluconazolewassubsequentlyadded.
However, he soon developed dry cough and
shortness of breath. He was cyanosed with
bronchial breathing in the right lung, (PO2 31
mmHg, PCO2 35 mmHg). Chest radiograph
showed diffuse bilateral patchy shadowing
suggestiveofPCP. Herespondedtohighdoseco-
trimoxazole and adjuvant corticosteroid within
48hours. He was doing well at37 months follow-
up.
Patient 3
A 29 year old male with acute lymphoblastic
leukaemia developed dry cough, dyspnoea and
recurrentpyrexiaeightmonthsintochemotherapy
as perthe UKALL 12 protocol. Chestradiograph
revealedperihilar shadowing suggestive ofPCP.
High dose co-trimoxazole and adjuvant steroid
resulted in rapid resolution of symptoms. An
allogeneic bone marrow transplantation was
performed. The patient was well at 42 months
follow-up.
Patient 4
A 38-year-old male with chronic psychosis
presented with a large cervical mass shown to be
high-grade non-Hodgkins lymphoma. After five
courses of 'CHOP' chemotherapy (cyclo-
phosphamide 750mg/M2, doxorubicin 50mg/M2,
vincristine 1.4 mg/M2 and prednisolone 40 mg/
mi2), he became unwell, with pyrexia and cough
productive ofgreen sputum. He smoked heavily
and refused food, resulting in significant weight
loss. His lactate dehydrogenase level (LDH)
which had become normal following cytotoxic
chemotherapy became raised once again, raising
suspicion of a lymphoma recurrence. Chest
radiograph was normal. CT scan which was
carriedouttoreassesshislymphomasurprisingly
revealed several areas of bilateral ground-glass
opacity suggestive of PCP. High dose co-
trimoxazole was instituted immediately. His
pyrexia settled.
Patient 5
A 36-year-old male with multiple myeloma was
treated with four courses of chemotherapy
(vincristine, adriamycin and dexamethasone)
followed by allogeneic bone marrow
transplantation. Methotrexate, cyclosporin and
prednisolone were used to prevent graft versus
host disease. He received cytomegalovirus
specific intravenous immunoglobulin and
prophylactic co-trimoxazole. He experienced
occasional nausea and vomiting after
transplantation but tried his best to comply with
his medication.
Tenweekslaterhebecameunwell,withshortness
of breath on exertion, pyrexia and cough
productive of purulent sputum. On examination
hehad sinustachycardiaandbasalcrepitations at
both lung bases. Chest radiograph showed
bilateral chronic inflammatory changes.
Computed tomography revealed peripheral ill-
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TABLE I
Lactate dehydrogenase level at different clinical stages illustrating a-transient elevation during
infection with PCP
LDH level At Post- During Post-high dose
u/l presentation chemotherapy PCP Co-trimoxazole
Patient 1 (AML) 2023 250 704 312
Patient 2 (ALL) 1939 758 1601 477
Patient 3 (ALL) 1749 378 1296 502
Patient4(NHL) 2702 684 1143 415
Patient5 (MM) 989 1161 963
(LDH normal range in our laboratory 360-720 u/i)
TABLE II
Haematologicalparameters at diagnosis ofPCP showing recovery ofneutrophil count but
persistent lymphopeniafollowing myelosuppressive chemotherapy
Total leucocyte Neutrophil Lymphocyte Monocyte Eosinophil
103/ul 103/ul 103/ul 103/ul 103/ul
Patient 1 (AML) 4.9 3.38 0.59 0.69 0
Patient2(ALL) 2.7 2.51 0.11 0.03 0.05
Patient 3 (ALL) 12.7 9.9 1.65 0.76 0.38
Patient 4 (NHL) 5.7 4.1 0.86 0.63 0.06
Patient 5 (MM) 3.1 2.79 0.09 0.16 0.03
Normal range: Total leucocyte 4-11
(103/ul) Neutrophil 1.7-6.1
Lymphocyte 1-3.2
Monocyte 0.2-0.6
Eosinophil 0.03-0.46
defined opacities and interstitial changes in the
peribronchial region and mid zones. Penicillin
resistant streptococcuspneumoniae was isolated
frombloodculture. Itwas sensitivetocefotaxime
and he was treated accordingly. Liposomal
amphotericin was added later when his pyrexia
failed to settle. Fluorescent antibody testing of
the sputum for PC was positive. He was
commenced on high-dose co-trimoxazole with
dose modification for impaired renal function.
He made a good recovery and remained well at
38-months follow-up.
The common features of the above patients are
summarised below:
1. All had intensive chemotherapy which had
beenstartedatleast6weeksbeforedeveloping
PCP.
2. All had been on a corticosteroid.
3. All showed a transient elevation in lactate
dehydrogenase level (LDH) during
pneumocystis infection without evidence of
underlying disease recurrence (Table I).
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4. Allfailedtorespondtoinitialbroadspectrum
anti-bacterial and anti-fungal agents but
improved afterhigh dose co-trimoxazole and
adjuvant corticosteroid.
5. A recovering leukocyte count after cytotoxic
treatmentdidnotcurtailtherespiratoryillness.
6. All had been in the same four-bedded male
bay or in the cubicles opposite, which were
managed by the same nursing team (the
nursing responsibility in the ward is divided
into team A and team B). Patients 1, 4 and 5
werehospitalised ataroundthe sametime and
developed PCP within a space of 2 months.
Patients 2 and 3 started induction
chemotherapy in the same month. They
subsequentlydevelopedPCPonemonthapart.
All cases occurred within a 6-month period.
Allpatientshadspentmanymonthsinandout
of haematology ward receiving treatment as
dictated by current cytotoxic protocol. In the
case ofpatient 4 with lymphoma, his chronic
psychosis and social circumstances
necessitated in-patient supervision of
treatment, which otherwise would have been
administered as an outpatient.
DISCUSSION
The data on the incidence of PCP in haemato-
oncology patients is quite scanty. A report in
1995 followed up 214 adult patients with acute
lymphoblastic leukaemia (ALL). 5% were
diagnosed withPCP at somepointduringthe two
yearsoftreatment.2Anothergroupofinvestigators
from Helsinki looked for PCP in 29 new adult
ALL and 44 acute myeloid leukaemia (AML)
from July 1990 to December 1993. PCP
prophylaxis was not included in the therapeutic
protocol. 24% ALL and none with AML
developed PCP.3 This incidence is similar to
childhood ALL in which 21% developed PCP
prior to co-trimoxazole prophylaxis.4
All patients reported above had been started on
intensive cytotoxic regime and corticosteroid at
least6weekspriortotheonsetoftheirrespiratory
illness. To the best of our knowledge, PCP has
never been reported in untreated patients with
leukaemia or lymphoma. This suggests the
patients' susceptibility to PCP is more closely
related to the type and the intensity of treatment
than to their haematological malignancy. Over
the years, little has changed in the treatment of
non-Hodgkin's lymphoma. CHOP type regime
remains the cornerstone, which is less intensive
and the duration ofleucopenia is short compared
tothetreatmentprotocols foracutelymphoidand
myeloid leukaemias. However, patient 4 with
non-Hodgkin's lymphoma illustrates that
malnutrition and heavy smoking may be adding
to his susceptibility to pneumocystis infection.
He suffers from chronic schizophrenia and his
behaviouralproblemshadcontributedtohiseating
disorder and subsequent weight loss.
The chest radiograph in PCP maybe normal and
hence unhelpful in the early stages. It typically
shows bilateral perihilar interstitial infiltrates,
progressing to diffuse confluent alveolar
shadowing as patients deteriorate clinically. Our
experience with patients 4 and 5 above indicates
that CT scanning may be more sensitive than
plain x-ray inrevealing theinterstitial changes in
early or subacute PCP.
Serum LDH level is a non specific test useful for
monitoring the cell turnover rate and the disease
activity in malignant haematological disorders.
Ithas alsobeennotedtoberaisedin HIVpositive
patients who develop pneumocystosis. Hence an
increase in the LDH level in patients whose
underlying disease has attained complete
remission should alert the clinician to the
possibility ofpneumocystis infection.
Ingeneral, mostpatientswithbacterialandfungal
infectionsassociatedwithcytotoxictherapyshow
clinical improvement coinciding with a rise in
their leukocyte counts from their lowest level.
From our experience, the recovery of haemato-
logical parameters, notably the neutrophil count
(Table II) following chemotherapy, did not
prevent or curtail PCP as would be expected in
bacterial infections. Absolute lymphopenia was
found in 4 out of the 5 patients at diagnosis of
PCP. This supports the view that cell-mediated
immunity is most important for protection from
PC. Although the lymphocyte subsets were not
measured in our patients, solid data from HIV
patientshadshownthattheriskofPCPcorrelates
with CD4 T lymphocyte count of <200/ul
(multicentreAIDSCohortStudy).Limitedreports
incancerpatientssuggestasimilarrelationship.5'6
However, the predictive value ofCD4 count has
not been evaluated in non-HIV patients.
Most of the experience in managing PCP also
camefromHIVpatients. Someclinicians strongly
advocate that all who present with symptoms and
chest x-ray or arterial blood gas findings
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suspicious ofPCPshouldhave abronchoscopy to
demonstrate the presence of PC in bronchial
secretions or tissue. Others have suggested that
suchpatientsmaybetreatedempirically,reserving
bronchoscopy for those with atypical
presentations and those who do not respond or
deteriorate on specific therapy.7 In clinical
practice both strategies seem equally effective.8
Many centres in UK and USA treat PCP
empirically.9
Exercise-induced arterial desaturation detected
by oximetry inpatients with normal resting PaO2
mayhelptodetectPCP. Inthelungfunctiontests,
the carbon monoxide transfer factor (TLCO),
total lung capacity and forced vital capacity may
be reduced, whereas peak expiratory flow and
forced expiratory volume in 1 second are
frequently normal. A reduction in the TLCO is
the most sensitive marker of PCP but this lacks
specificity as it is also decreased in bacterial
infections. Weneeda sensitive, reliable andnon-
invasive tool for early diagnosis of PCP, as
patients with malignant haematological
conditions immune-compromised by intensive
chemotherapy can deteriorate very rapidly.
Sputum induction is uncomfortable and the yield
is poor. Bronchoalveolar lavage is not always
possible asthesepatients maybetootachypnoeic
and hypoxic. Transbronchial biopsy may be
contraindicated by thrombocytopenia or
coagulopathy. Openlungbiopsy,thoughthemost
sensitive andspecific, is alsothemosthazardous.
Many clinicians believe that transbronchial and
open lung biopsies have little to add to
bronchoscopy and bronchoalveolar lavage. In
practice, empirical treatment must be started
without delay. Recent studies showed that it is
possible to amplify pneumocystis carinii DNA
by PCR directly from blood and nasopharyngeal
aspirates ofPCPpatients. 10,11 However, cost and
availability are limiting factors. There is no
established culture system for pneumocystis
carinii thatwould allow traditional antimicrobial
sensitivity testing. This and a serologic test that
will distinguish recent from past infections are
needed.
PCP is fatal in almost all cases if left untreated.
Adjuvant use of steroid has contributed to
decreasedmortalityrateandhasreducedtheneed
for assisted ventilation in the most severe cases.
The mechanisms for this paradoxical response
may be attributed to a reduction in the cellular
infiltrates within alveolar spaces, allowingbetter
gas exchange and improving chest expansion.
Patient 5 illustrates a well-recognised
complication following bone marrow
transplantation, that offunctional hyposplenism
relatedtototalbodyirradiation. Thispredisposed
theindividualtoinfectionbycapsulatedbacteria,
especiallypneumococci. Thesuperinfectionwith
pneumococcihadenabledproductionofsufficient
amount of sputum to allow confirmation ofPCP
by fluorescent antibody testing. Although he had
been on prophylactic co-trimoxazole since his
bonemarrowtransplant, his susceptibility toPCP
was probably increased as a result of
hyposplenism.
It is possible that PCP in immune-compromised
patients arises by reactivation of a latent
asymptomatic infection acquired in childhood.
This hypothesis is supported by the finding of
antibodies to PC in most healthy children and
adults.12 Immunosuppression in later life may
lead to clinical manifestations. However, over
the years a steady flow of reports has described
clusters of PCP cases not readily explained by
reactivation of latent infections. Recent studies
have suggested that the duration of latency is
verylimited, usuallylessthanoneyear.13 14There
may be an alternative explanation.
Althoughperson-to-person transmission ofPC is
yet to be proven in human, we are concerned
about the clustering ofcases in the ward within a
space of 6 months. PC DNA has been identified
fromambientairsampledfromrural Oxfordshire
in the UK,15 and from rooms of animals and
patients with PCP in United States.'6 Recent
studies have demonstrated genetic variation in
PCR-amplifiedpneumocystis cariniiDNAfrom
the lungs of patients during recurrent PCP
episodes.17 All these data indicate that PC is
causedby airborne organisms andthatperson-to-
person transmission of pneumocystis carinii is
possible. At least some cases of PCP are due to
acquisition of new infection from an exogenous
sourceratherthanrelapseofanexistinginfection.
This has significant implications on the
management of immune-compromised patients
in the haematology ward. Studies are needed to
decide whether case to case transmission
contributes to infection significantly more than
airborne sources in the environment.
Consequently, preventative measures and
decontamination procedures might be drawn up
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to protect patients. Until the epidemiologic
features and mode ofacquisition ofPC are better
understood, antimicrobial drugs remain the only
available method for PCP prophylaxis. Some
haematologists arereluctanttouseco-trimoxazole
for fear of exacerbating myelosuppression and
inducing antimicrobial resistance. Besides,
pneumocystis infectioninnon-HIVhaematology
patients appears to be sufficiently uncommon to
justifyprolongeduseofco-trimoxazole. Weneed
to define the risk factors in order to target a
subgroup of patients for PCP prophylaxis after
institution of cytotoxic therapy.
The risk factors we have identified are:
1. Lymphoproliferative malignancies after
intensive chemotherapy.
2. Corticosteroid therapy.
3. Bone marrow transplantation.
4. Lymphopenia.
5. Poor nutrition and possibly smoking.
Inconclusion, PCPis apreventablecomplication
in patients treated with cytotoxic chemotherapy
and corticosteroid. It should be considered in the
differential diagnosis of pneumonia. A rise in
LDHlevelinpatientswhohaveattainedremission
from their haematological malignancy should
prompt a search for PC, as rapid deterioration
may ensue if treatment is delayed. Prophylaxis
for PCP is now routinely started in our unit in
selected high-risk patients approximately one
month following institution of intensive
chemotherapy.
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